Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Unmet Needs Council OKs Public Knowledge-Based Filings for 2 Antiemetics
July 15, 2021
- ICMRA Discussing Substitutes for Placebo-Controlled Trials of COVID Vaccines: MHLW
July 15, 2021
- Forxiga’s CKD Indication Up for PAFSC Review on July 28, Possible OK in August
July 15, 2021
- Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
July 9, 2021
- Japan PM “Watching Expert Discussions” on AstraZeneca Vaccine Use
July 9, 2021
- Japan OKs FY2022 Budget Guidelines, 660 Billion Yen Cap for Social Security Cost Rise
July 8, 2021
- MHLW Announces 1st Revision of Dyslipidemia Drug Development Guidelines in 30 Years
July 8, 2021
- Label Revisions Ordered for Myocarditis/Pericarditis Risks of Pfizer, Moderna’s COVID Vaccines
July 8, 2021
- MHLW’s COVID-19 Guide Recommends against Camostat after Trial Failures
July 7, 2021
- Health Minister Hints at Priority Vaccine Supply to Municipalities Making Headway
July 7, 2021
- MHLW Ups Ante for Regulatory Reviews of Jointly Developed Generics
July 7, 2021
- Leigh Syndrome Drug PTC743 Gets Orphan Status
July 6, 2021
- Draft Revision of MHLW’s Distribution Guidelines Stresses Compliance with Antitrust Act
July 5, 2021
- Govt to Provide Vaccines for All Workplace Programs Requested
July 5, 2021
- MHLW Urges Wholesalers to Strictly Enforce Legal Compliance after Bid-Rigging Ruling
July 2, 2021
- Sakigake Tag Revoked for Eisai’s E7090 after Pemazyre Approval
July 1, 2021
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- MHLW to Start Study on US, European Schemes on ADR Evaluation
June 29, 2021
- MHLW Extends Maximum Biz Suspension Period to 180 Days in All Prefectures
June 29, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…